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Rather than create
a new entity of
uncertain
deﬁnition called
“translational
research,” perhaps
new and existing
studies could be
graded on the
degree to which
they are
translational.For most of my 30-plus years in cardiology I have considered myself a clinicalinvestigator. Following an early career that dealt almost exclusively with patient-based research, I turned to the animal laboratory after becoming more involved with
technology. Although working with a variety of experimental protocols, all were directed
toward human disease, and I knew for sure that I was not a basic scientist. Then, several
years ago, through reading and at meetings, I learned that translational research was the
“wave of the future.” The National Institutes of Health (NIH) had established the Clinical
and Translational Science Award (CTSA) program, and a number of very wise people
strongly encouraged me to direct my investigative efforts toward translational research.
Although I was ready and willing to do so, only one problem existed: no one could give me
a precise deﬁnition of exactly what translational research was.
The term “translational research” ﬁrst appeared in PubMed in 1993, and it has become
increasingly common in that venue since 2000. It has been written repeatedly that translational
research lacks a clear deﬁnition, and that if you ask 10 people you will probably get 10 different
responses (1–3). In its simplest form, translational research represents a fundamental concept
that I have encountered since entering medicine: the conversion of discoveries from “bench to
bedside.” However, this concept is all-encompassing and non-speciﬁc. According to the
Merriam-Webster dictionary, translational medical research is “concerned with facilitating the
practical application of scientiﬁc discoveries to the development and implementation of new
ways to prevent, diagnose, and treat disease” (4). The universal bible of information,
Wikipedia, deﬁnes it as “scientiﬁc research that helps to make ﬁndings from basic science
useful for practical applications that enhance human health and well-being” (5). However, all
of these deﬁnitions are non-speciﬁc, and as is so often the case, the devil is in the details.
An attempt to more exactly specify the components of translational research is complicated
by uncertainty regarding the nature and boundaries of other terms used to characterize
investigation. Thus, one can read that translational activities serve as a bridge between basic
(sometimes called fundamental) and applied research, but the deﬁnition of these entities is
not necessarily precise. For example, one deﬁnition states that fundamental research is driven
by scientiﬁc curiosity and does not necessarily have any obvious practical value (2). However,
I doubt that many of my colleagues who consider themselves basic scientists would fully agree
with that description. Other terms that are frequently encountered are pre-clinical and clinical
research. It is not clear, though, if pre-clinical research is basic or applied. Neither, in my view,
is there universal agreement as to whether health services and cost-effectiveness studies are
included in clinical research. Finally, some descriptions of translational activities focus on the
development of products and bringing them to the market. This clearly represents an
extremely focused notion of what constitutes translational research.
In an attempt to bring some clarity to the concept of translational investigation, the
Institute of Medicine convened a Clinical Research Roundtable. This group identiﬁed
2 “translational blocks,” termed T1 and T2, that existed in the research enterprise and could
form the basis of a more detailed deﬁnition of translational research (1). T1 consisted of
a block in “the transfer of new understandings of disease mechanisms gained in the laboratory
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2343into the development of new methods for diagnosis, therapy,
and prevention and their ﬁrst testing in humans.” T2 was
described as an obstruction to “the translation of results from
clinical studies into everyday clinical practice and health
decision making.” Studies aimed at overcoming T1 and T2
blocks would therefore constitute translational research.
Roughly, T1 could be viewed as patient-oriented research
and T2 as population-based investigation. Nevertheless, it
remains uncertain how nonhuman research with clinical
implications is classiﬁed.
To a certain extent, the concept of translational investi-
gation could be seen as old wine in new bottles. The attempt
to develop a clear new concept is impacted by the fact that
the path from basic science discovery to full incorporation
into daily clinical medical practice is a continuum. The
National Cancer Institute has portrayed the process in steps
designated as basic science discovery, early translation, late
translation, dissemination, and adoption. So, it appears that
the vast majority of biomedical research currently being
performed could ﬁt somewhere in this spectrum. It seems to
me that basic scientists have always had a keen focus on any
potential clinical implications of their experiments and
ﬁndings. Similarly, clinical investigators have always been
searching for new innovations that could be applied to
human health. With the recent emphasis upon cost
containment and outcomes, studies directed at these issues
have increased dramatically. So, although much of the
current research may not bear the designation “trans-
lational,” it is likely that it is accomplishing the same goal.
My previous comments are not meant to diminish the
need that exists to convert basic biological discoveries into
preventive, diagnostic, or therapeutic modalities to improve
human health. Whether counting new patents or new drugs/
devices approved for patient care, a consensus exists that
there has been a signiﬁcant disproportion between the large
number of new basic science insights and mechanisms and
the relatively small number of new modalities that beneﬁt
patients (1–3,6). As expressed by 1 observer, the NIH is the
National Institutes of Health, not the National Institutes of
Biomedical Research (3). Of perhaps even greater impor-
tance, there is a pressing need to educate and train clinical
investigators to be able to provide the expertise to transform
basic science breakthroughs into better human health. If
conceptualizing the effort to meet these needs under the
rubric of translational research helps to accomplish this goal,
then the lack of clear deﬁnition may be a small price to pay.
It has occurred tome that theremaybe an alternate approach
to bridging the chasm between basic and clinical investigation.
Rather than create a new entity of uncertain deﬁnition called
“translational research,” perhaps new and existing studies could
be graded on the degree to which they are translational. Basicfundamental ﬁndings that have no immediate implications for
human health would have a very low grade. Pre-clinical
experimental studies directed toward conversion to clinical
applicationwould receive good grades. Initial human studies to
test the safety and efﬁcacy of novel drugs or methods and
provide the crucial link between the bench and the bedside
would garner the highest grades. If the desire is to emphasize
investigation that transforms basic discoveries into clinical
modalities, resources could be allocated based upon the degree
to which a project was “translational.”
The deﬁcit in the conversion of basic science discoveries
to novel approaches that improve human health generated
the concept of, and emphasis upon, translational research.
At present, the deﬁnition of translational research appears to
reside in the eye of the beholder. This is analogous to
pornography: although I cannot precisely deﬁne it, I know it
when I see it. The problem lies not in the overall concept,
but in the speciﬁc details. Despite this lack of clarity, huge
NIH programs, such as CTSAs, medical school units, and
new medical journals, have all been created that are dedi-
cated to translational research. In fact, translational research
may have received more attention and more resources than
any other entity without exact deﬁnition in the history of
medicine. Nevertheless, the issue that it addresses is serious,
pressing, and most worthy of the effort and attention. I
believe that, rather than create a new entity whose deﬁnition
is not agreed upon, it would be better to classify investigation
into the well-characterized and accepted existing categories
and to assess each project based upon the degree to which it
was translational. However, that, like most things about
translational research, is just one man’s opinion. Regardless
of how the ﬁeld evolves, for the foreseeable future whenever
I hear the term I guess I will continue to have the same
response: “What do you mean by translational research?”
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